Research programme: cancer therapeutics - Hanmi Pharmaceuticals

Drug Profile

Research programme: cancer therapeutics - Hanmi Pharmaceuticals

Alternative Names: BTK/JAK dual inhibitor - Hanmi; EGFR mutant selective inhibitors - Hanmi; IAP inhibitor - Hanmi; Inhibitors of apoptosis protein inhibitors - Hanmi

Latest Information Update: 05 Jul 2011

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Epidermal growth factor receptor antagonists; Inhibitor of apoptosis protein inhibitors; Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 29 Jun 2011 Early research is ongoing in South Korea
  • 09 Aug 2010 Early research in Cancer in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top